

Patient Age/Sex: 7 days Male

Specimen Collected: 11/22/2024 12:14 MST

Panel and THC, Meconium, Qual | Received: 11/22/2024 12:14 MST Report/Verified: 11/22/2024 13:37 MST

Procedure	Result	Units	Reference Interval
6-Acetylmorphine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
7-Aminoclonazepam, MEC, Qual	Not Detected	ng/g	[Cutoff 5]
Alpha-OH-Alprazolam, MEC, Qual	Not Detected	ng/g	[Cutoff 5]
Alpha-OH-Midazolam, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Alprazolam, MEC, Qual	Not Detected	ng/g	[Cutoff 5]
Amphetamine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Benzoyllecgonine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Buprenorphine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Butalbital, MEC, Qual	Not Detected	ng/g	[Cutoff 50]
Clonazepam, MEC, Qual	Not Detected	ng/g	[Cutoff 5]
Cocaethylene, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Cocaine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Codeine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Diazepam, MEC, Qual	Not Detected	ng/g	[Cutoff 5]
Dihydrocodeine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Drug Detection Panel, MEC	See Below ⁱ¹		
Fentanyl, MEC, Qual	Not Detected	ng/g	[Cutoff 10]
Gabapentin, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Hydrocodone, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Hydromorphone, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Lorazepam, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
MDMA-Ecstasy, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Meperidine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Methadone Metabolite, MEC, Qual	Not Detected	ng/g	[Cutoff 10]
Methadone, MEC, Qual	Not Detected	ng/g	[Cutoff 10]
Methamphetamine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Methylphenidate, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Midazolam, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Mitragynine, MEC, Qual	Not Detected	ng/g	[Cutoff 25]
Morphine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
N-desmethyltramadol, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Naloxone, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Norbuprenorphine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Nordiazepam, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Norhydrocodone, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Noroxycodone, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
O-desmethyltramadol, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Oxazepam, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Oxycodone, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Oxymorphone, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Phencyclidine-PCP, MEC, Qual	Not Detected	ng/g	[Cutoff 10]

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 24-327-900128

Report Request ID: 20189757

Printed: 11/22/2024 13:42 MST

Page 1 of 3

Patient Age/Sex: 7 days Male

Panel and THC, Meconium, Qual | **Received: 11/22/2024 12:14 MST** **Report/Verified: 11/22/2024 13:37 MST**

Procedure	Result	Units	Reference Interval
Phenobarbital, MEC, Qual	Not Detected	ng/g	[Cutoff 200]
Phentermine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Tapentadol, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Temazepam, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Tramadol, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Zolpidem, MEC, Qual	Not Detected	ng/g	[Cutoff 10]
m-OH-Benzoylecgonine, MEC, Qual	Not Detected	ng/g	[Cutoff 20]
Carboxy-THC, MEC	Not Detected ⁱ²	ng/g	
EER Drug Panel and THC, Meconium See Note			

Test Information

i1: Drug Detection Panel, MEC
INTERPRETIVE INFORMATION: Meconium Drug Panel

Methodology: Qualitative liquid chromatography/tandem mass spectrometry

Detection of drugs is intended to reflect maternal drug use during approximately the last trimester of a full-term pregnancy. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs depends on the extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in meconium, and the performance of the analytical method. Drugs administered during labor and delivery, or drugs administered directly to the infant after birth may be detected. Detection of drugs in meconium does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: Carboxy-THC, MEC
INTERPRETIVE INFORMATION: Carboxy-THC, MEC

1. Positive cutoff: 5 ng/g.

2. Methodology: Mass spectrometry

3. This test is designed to detect and document exposure that occurred during approximately the last trimester of a full-term pregnancy to a common metabolite of THC (which may be present in cannabis products). Alternative testing is available to

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 24-327-900128**Report Request ID:** 20189757**Printed:** 11/22/2024 13:42 MST

Page 2 of 3

Test Information

i2: Carboxy-THC, MEC

detect other drug exposures. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in meconium depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in meconium, and the performance of the analytical method. Drugs administered during labor and delivery, or drugs administered directly to the infant after birth may be detected. Detection of drugs in meconium does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory. This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites. For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 24-327-900128

Report Request ID: 20189757

Printed: 11/22/2024 13:42 MST

Page 3 of 3